The recent Presidential Executive Memorandum and FDA crackdown on deceptive practices in direct-to-consumer (DTC) pharmaceutical advertising mark a pivotal moment for our industry. Over the past few days, I’ve had countless discussions with clients, peers, and industry leaders about the future of DTC marketing. Faced with potential changes to DTC advertising regulations affecting TV and social media in particular, increasing requirements for data privacy in health, and rapidly evolving technology, our industry is experiencing a convergence of factors that is unique in both speed and complexity. This evolution is unlike anything we have experienced before; and while the impact of these forces remains to be seen, one thing is abundantly clear: the landscape of health advertising is evolving, and it’s doing so for the better.

The core of the new approach is the elimination of a “loophole” that has been in place since 1997, which allows pharmaceutical companies to provide a brief statement of major risks in TV ads and direct viewers to a website, toll-free number, or printed materials for more complete information. The new regulations will likely require drug companies to include all critical safety facts directly within the advertisement itself. Think about the likely outcome: a 2+ minute ad is a terrible patient experience, and likely provides no ROI. Let’s be honest dear friends, colleagues, and partners, these ads do not belong in the Super Bowl or the NCAA Tournament or...
Create your FREE account to continue reading and explore more expert insights on Pharma Media.
✅ Free. Fast. No commitment.